Viking Therapeutics begins VK2735 maintenance study
Viking Therapeutics has initiated the second part of its VK2735 maintenance study for obesity, exploring oral and less frequent injectable formulations to maintain weight loss achieved through initial weekly injections. The study will enroll 195 adults and track weight change through week 33, focusing on safety, tolerability, and pharmacokinetics, with weight change as an exploratory measure. This follows positive results from the first part of the study where participants lost 16-19% of body weight with weekly injections, and subsequent maintenance with injections every other week or monthly largely preserved this loss.
Viking Therapeutics starts study on oral and subcutaneous VK2735 dosing for obesity maintenance.
Viking Therapeutics has initiated the second part of a study investigating oral and subcutaneous VK2735, a dual GLP-1/GIP receptor agonist, for maintaining weight loss in obese adults. This randomized, placebo-controlled trial builds on positive results from Part 1 and aims to develop flexible maintenance options to improve long-term adherence and weight management. The company is also conducting two Phase 3 trials for weekly subcutaneous VK2735 in obesity treatment.
Viking Therapeutics starts oral VK2735 maintenance dosing trial
Viking Therapeutics has initiated Part 2 of an exploratory maintenance dosing study for its dual GLP-1/GIP receptor agonist, VK2735. This trial will enroll 195 adults with obesity to evaluate various oral and subcutaneous maintenance regimens after an initial 21-week treatment period. Results from Part 2 are anticipated in 2027, complementing ongoing Phase 3 trials for the subcutaneous version of VK2735.
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
Viking Therapeutics has initiated the second part of its VK2735 oral maintenance dosing clinical trial for obesity, exploring various oral and subcutaneous regimens to maintain initial weight loss. This randomized, double-blind, placebo-controlled study will involve approximately 195 adults with obesity, assessing safety, tolerability, and pharmacokinetic profiles. The company aims to provide flexible and optional treatment approaches to enhance long-term weight management and adherence.
Significant stock movers of September: Viking soars, Longeveron slides
September saw significant movements in biopharma stocks, with Viking Therapeutics experiencing a 24% surge while Longeveron plunged by 64%. Viking's rise was driven by strong Phase 1 obesity data and a subsequent successful capital raise, despite a slight dip at month-end due to stock dilution. In contrast, Longeveron's stock plummeted following the failure of its investigational stem cell therapy in a Phase 2b trial for a rare congenital heart disorder, leading the company to review its options with limited cash reserves.
Viking Therapeutics (VKTX) On Fresh VK2735 Data And New Funding Still Looks Pricey
Viking Therapeutics (VKTX) recently announced positive data for its VK2735 obesity drug and secured over US$500 million in new funding. Despite these positive developments, the stock's share price has fallen recently and its valuation remains high, with a Price-to-Book ratio of 8.6x compared to a sector average of 2.1x. A Discounted Cash Flow analysis also suggests the stock is overvalued at $7.34 per share compared to its current price of $29.94.
Viking Therapeutics stock faces dilution after USD 575.0 million raise
Viking Therapeutics recently completed a $575.0 million stock and convertible-note offering to fund its pipeline, including VK2735 and VK3019. This financing, which closed on September 28, 2026, has led to stock dilution, with shares trading below the offering price. Despite this, positive maintenance data for VK2735, showing significant weight loss retention with flexible dosing, and strong analyst price targets suggest potential future growth for the company.
VKTX - Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis
Viking Therapeutics (VKTX) is positioned for long-term growth due to its expanding obesity pipeline, particularly with VK2735 entering late-stage trials for both subcutaneous and oral formulations. Analysts forecast revenue reaching $118.5 million by March 2029, despite the company currently having no revenue and ongoing net losses. The success of VK2735 and strategic manufacturing agreements are key to future profitability and market penetration in the competitive obesity treatment landscape.
Weight Loss Maintenance Data Could Be A Big Test For Viking Therapeutics Stock (VKTX)
Viking Therapeutics recently completed a US$500 million capital raise through convertible notes and equity, following positive VK2735 weight maintenance data in obesity. This funding provides the company greater flexibility for larger trials and pipeline expansion, despite operating at a loss. The article explores how this capital infusion and the VK2735 data impact Viking Therapeutics' investment narrative, emphasizing dilution risks and the assumptions underlying its financial forecasts.
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
Viking Therapeutics, Inc. (VKTX) saw a 2.92% gain, closing at $32.74, outperforming the S&P 500's daily loss. Despite a recent monthly decline, analysts are forecasting -$1 per share for its upcoming earnings report, with full-year projections of -$4.47 per share and $0 million in revenue. The company currently holds a Zacks Rank of #2 (Buy), indicating a positive outlook based on recent analyst estimate revisions.
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Viking Therapeutics (VKTX) stock surged 36% after releasing promising data for its weight-loss drug candidate, VK2735, showing strong weight maintenance with less frequent dosing. The clinical-stage biotech aims to differentiate itself in the competitive weight-loss market by offering a maintenance dosing option, potentially attracting patients from competitors. While the initial results are positive, investors should be aware of potential risks like share dilution and the need for successful larger-scale clinical trials.
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks
Viking Therapeutics (VKTX) shares experienced a three-day losing streak after the company closed a $548 million capital raise, including stock and convertible notes, primarily to fund its VK2735 and VK3019 obesity programs. Despite the dip, retail investors on Stocktwits expressed bullish sentiment, viewing the decline as a buying opportunity given the company's newfound funding and positive analyst reactions to recent clinical trial results for VK2735. Analysts raised price targets following "impressive" maintenance results for VK2735, indicating significant upside potential for the stock.
About $575 million came in for Viking Therapeutics, including $258.75 million in debt that can turn into shares.
Viking Therapeutics (VKTX) successfully closed concurrent offerings of common stock and convertible senior notes, raising approximately $575.0 million in gross proceeds. After deducting expenses, the net proceeds are estimated at $547.8 million, which the company plans to allocate towards the continued clinical development of its VK2735 and VK3019 programs, as well as for general research, working capital, and corporate purposes. The offerings included the full exercise of underwriters' options for additional shares and notes, highlighting strong market interest.
Viking Therapeutics raises $575 million in dual offering By Investing.com
Viking Therapeutics Inc. successfully completed dual public offerings of common stock and convertible senior notes, raising approximately $575 million in gross proceeds. The biopharmaceutical company plans to use these funds for the clinical development, advancement, and commercialization of its VK2735 and VK3019 programs, as well as for general research and development, working capital, and corporate purposes. VK2735 is currently in Phase 3 clinical studies for obesity.
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Viking Therapeutics announced the closing of its upsized public offerings of common stock and convertible senior notes, including the full exercise of underwriters' options, resulting in approximately $575 million in gross proceeds. The company plans to use the estimated net proceeds of $547.8 million for the continued clinical development and advancement of its VK2735 and VK3019 programs, along with other general research and development, working capital, and corporate purposes. These offerings were made pursuant to an effective shelf registration statement with the SEC.
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Viking Therapeutics has announced the closing of its concurrent upsized public offerings, which included the full exercise of underwriters' options for both common stock and convertible senior notes. The offerings generated approximately $575.0 million in gross proceeds, with net proceeds estimated at $547.8 million. The funds will be used for the clinical development and commercialization of its VK2735 and VK3019 programs, as well as for general research and development and corporate purposes.
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, has initiated an investigation into whether officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term VKTX stockholders to contact them for a free consultation, as they may be entitled to damages and corporate governance reforms. Kuehn Law emphasizes the importance of shareholder participation in maintaining the integrity of financial markets.
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking Therapeutics' stock recently surged by 35% following promising maintenance dosing data for its GLP-1 drug candidate, VK2735. The drug showed high weight loss maintenance with reduced dosing frequency, positioning Viking as a potential competitor in the GLP-1 market currently dominated by Eli Lilly and Novo Nordisk. Investors are now evaluating if it's still a good time to invest in Viking, given the stock's volatility and the inherent risks of biotech investments, though future catalysts like regulatory approval could drive further growth.
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
Viking Therapeutics (VKTX) dropped 15% after pricing an upsized $500 million offering of common stock and convertible senior notes, indicating a dilutive response from shareholders. Concurrently, Jaguar Health (JAGX) plummeted 25% due to micro-cap trading mechanics, not a new catalyst, following a recent reverse stock split. The article highlights that these declines are company-specific events, as the overall biotechnology sector benchmark (IBB) saw a slight increase.
Viking Therapeutics Sinks 12% on “Upsized” $500 Million Raise
Viking Therapeutics (VKTX) shares dropped 12% after the company upsized its equity offering to $500 million, initially seeking $400 million. The raise, including new shares at a 16% discount and convertible notes, aims to fund the development and commercialization of its VK2735 and VK3019 programs. Despite the dilution, the article suggests the significant capital infusion is a necessary step for the biotech firm's late-stage clinical trials and potential commercialization, especially given the large potential market for weight-loss drugs.
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
Viking Therapeutics (VKTX) stock fell 15% after pricing an upsized $500 million offering of common stock and convertible senior notes at $35.00 per share, leading to a dilution response from shareholders. Concurrently, Jaguar Health (JAGX) tumbled 25% with no immediate catalyst, attributed instead to its micro-cap mechanics and prior reverse stock split. Both declines are considered company-specific rather than indicative of a broader sector downturn, as the iShares Biotechnology ETF (IBB) saw a slight increase.
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
Viking Therapeutics, Inc. announced its intention to offer $200.0 million in common stock and $200.0 million in convertible senior notes due 2032. The company also plans to grant underwriters options to purchase additional shares and notes. Proceeds from both offerings will fund the clinical development and commercialization of its VK2735 and VK3019 programs, along with general R&D and corporate purposes.
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
Viking Therapeutics announced the pricing of upsized public offerings totaling $500 million, including common stock and convertible senior notes. The offerings aim to generate approximately $258.2 million from common stock and $218.0 million from notes, with funds earmarked for the clinical development of its VK2735 and VK3019 programs, as well as general research and corporate purposes. The notes will mature in 2032 with a 2.00% annual interest rate and an initial conversion price of approximately $50.75 per share, representing a 45% premium.
VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing
Viking Therapeutics (VKTX) stock experienced a significant drop after announcing an upsized $500 million stock and convertible debt offering at a 16% discount. This comes just days after the company reported promising phase 2 data for its weight-loss drug VK2735, which showed 16% to 19% weight loss in patients. The financing aims to advance VK2735 development, with retail sentiment on the offering being mixed despite the positive drug data.
VKTX Stock Slides After-Hours On $400M Stock-And-Notes Raise After Tuesday’s Rally
Viking Therapeutics (VKTX) shares fell sharply after-hours following the announcement of a $400 million stock and convertible notes offering. This move comes just one day after the company experienced a significant rally due to positive results from a maintenance study for its obesity drug, VK2735. The funds raised are intended to support the development and commercialization of VK2735 and other pipeline candidates, though investors reacted negatively to the potential dilution risk.
Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%
Jaguar Health and Viking Therapeutics experienced significant stock drops, 59% and 4% respectively, on Wednesday, but for different, company-specific reasons. Jaguar Health's decline is attributed to profit-taking after a recent surge, while Viking Therapeutics saw a pullback following positive news from its obesity drug trial. The broader biotechnology sector, as represented by the iShares Biotechnology ETF, remained largely stable, indicating these were isolated incidents rather than a widespread market downturn.
Viking Therapeutics Stock Surges 36% Following Weight Loss Drug Study Results
Viking Therapeutics (VKTX) stock surged 36% after releasing new data on its obesity drug, VK2735. The study showed that patients maintained significant weight loss even with less frequent dosing, which is a critical factor for long-term adherence to weight loss treatments. The company plans to further test oral maintenance dosing.
A weight-loss treatment showed 22% more loss than a placebo by week 33. No plateau was seen.
Viking Therapeutics (VKTX) announced positive topline results from a 33-week maintenance study of its GLP-1/GIP agonist VK2735 for obesity. The study demonstrated a 22% placebo-adjusted mean weight loss by Week 33 with no plateau, and patients maintained up to 97% of their weight loss with less frequent dosing regimens. The drug also showed an excellent tolerability profile during the maintenance phase, with gastrointestinal adverse event rates similar to placebo.
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
Viking Therapeutics announced positive top-line results from its maintenance study of VK2735, a dual GLP-1/GIP agonist, showing superior weight maintenance with less frequent dosing regimens. The study demonstrated up to 97% of weight loss maintained with every-other-week dosing and up to 90% with monthly dosing, with an encouraging safety and tolerability profile. These results highlight the potential for flexible long-term weight management options for patients with obesity, with GI adverse event rates similar to placebo during the maintenance phase.
Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher
Novo Nordisk's stock dropped 7% after its capital markets day where the company projected peer-average growth through 2030 and acknowledged the upcoming 2032 patent cliff for semaglutide, the active ingredient in Wegovy and Ozempic. This announcement fueled investor concerns about competition in the weight-loss market. While Eli Lilly, a direct competitor, saw only a slight dip, Viking Therapeutics rose, suggesting a rotation of capital towards next-generation obesity treatments.
Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss
Viking Therapeutics' VK2735, a GLP-1/GIP dual agonist, is moving into Phase 3 clinical trials for obesity after showing approximately 15% weight loss in Phase 2. The company is developing both injectable and oral formulations, with the injectable trials fully enrolled and results expected in late 2027, and oral trials set to begin in Q4. Viking is also exploring maintenance dosing strategies and building significant manufacturing capacity while remaining open to partnerships for commercialization.
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) experienced a 1.74% decline, underperforming the broader S&P 500, Dow, and Nasdaq in its latest trading session. Over the past month, the company's shares have fallen by 3.88%. Analysts project a 23.46% drop in upcoming EPS and a 40.13% decline in annual EPS, with the stock currently holding a Zacks Rank of #3 (Hold).
Viking Therapeutics options flow signals binary event bet ahead of VK2735 readout
Options trading activity for Viking Therapeutics (VKTX) suggests a significant binary event bet ahead of the imminent Phase 1 subcutaneous maintenance readout for VK2735. High call volume, a negative 90/110 skew, and fresh speculative positions indicate traders are positioning for a sharp rally on positive data, while also showing hedging for potential downside. The market perceives the upcoming data as a critical, high-volatility event for the stock.
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential breaches of fiduciary duties by officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) due to alleged self-dealing. Long-term VKTX stockholders are encouraged to contact the firm for a free consultation to explore potential damages and corporate governance reforms. The firm emphasizes that shareholder participation is crucial for financial market integrity.
Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run?
Viking Therapeutics (VKTX) stock has seen a 411% return over the last five years, leading to concerns about its current valuation. Despite a strong cash position and promising metabolic drug candidates, the stock appears overvalued based on its P/B ratio compared to peers and the broader biotech industry. The market seems to have already priced in much of the potential upside, making future clinical and regulatory outcomes crucial to justifying its premium valuation.
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong
The author argues against Wall Street analysts' predictions that Viking Therapeutics (VKTX) stock could triple in the next year, despite the company's promising weight-loss drug candidate, VK2735. The author believes that for the stock to achieve such gains, the phase 3 trial results for VK2735 would need to be exceptionally strong, matching or exceeding the best-in-class performance of rival drugs, which is an optimistic scenario. While VK2735 is a strong contender in the weight-loss market, investors should be aware of the high risks and volatility associated with clinical-stage biotech stocks.
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong
Three Wall Street analysts predict Viking Therapeutics (VKTX) stock could roughly triple in the next year, setting price targets around $100. However, the author expresses skepticism, arguing that for such a gain, the company's leading weight-loss drug candidate, VK2735, would need to deliver near-flawless phase 3 results, matching or exceeding the performance of best-in-class competitors like retatrutide, which is an optimistic scenario. While Viking Therapeutics has promising candidates in a growing market, its stock remains highly risky due to potential clinical setbacks.
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in three upcoming investor conferences in September 2026: the Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum. Management will engage in fireside chats and investor meetings at each event. A webcast of the Morgan Stanley conference fireside chat will be available on the company's website.
Viking Therapeutics Inc (XTER:1VT) Stock Price, Trades & News
This page provides a comprehensive overview of Viking Therapeutics Inc (XTER:1VT) stock, including its current price, key financial metrics like P/E and P/B ratios, market capitalization, and enterprise value. It also details the company's business description as a biopharmaceutical developer focused on metabolic and endocrine disorders, lists its financial strength, growth, momentum, liquidity, and profitability ranks, and highlights upcoming financial events and recent news releases. The stock is currently trading at €28.3, with a market cap of €3.32B.
Viking Therapeutics Inc (XTER:1VT) Stock Earnings Transcripts
This page provides a comprehensive list of earnings call transcripts and conference transcripts for Viking Therapeutics Inc (XTER:1VT) dating back to 2018. It includes transcripts for quarterly earnings calls, presentations at healthcare conferences, and specific trial results calls. Users can access these documents to review the company's historical financial discussions and corporate presentations.
Viking Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
This is a transcript of Viking Therapeutics Inc's presentation at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2019. An unidentified company representative discussed the San Diego-based biotech company's portfolio of small molecule drugs, emphasizing their focus on first-in-class or best-in-class therapeutics for metabolic and endocrine disorders, with data from two Phase 2 programs already reported.
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress
Viking Therapeutics (VKTX) shares rose slightly after-hours following updates on its obesity drug programs. The company confirmed that late-stage trials for its injectable obesity drug VK2735 are fully enrolled and progressing as scheduled, with plans for an oral version's late-stage trial by Q4 2026. Despite reporting a net loss of $128 million, investors remain focused on clinical progress as Viking has no approved drug products yet.
Viking Therapeutics (NASDAQ:VKTX) Upgraded to Hold at Zacks Research
Zacks Research has upgraded Viking Therapeutics (NASDAQ:VKTX) from a "strong sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with a target price of $96.62. The company's stock rose 7.8% on Tuesday after exceeding quarterly loss expectations. Despite recent insider stock sales totaling $6.27 million to cover tax obligations, institutional investors hold a significant 76.03% stake in Viking Therapeutics.
Viking Therapeutics (VKTX) Stock Still Looks Pricey With Pipeline Hopes Priced In
Viking Therapeutics (VKTX) stock appears expensive despite a significant 463.7% return over five years. The company fails most valuation checks, with its Price-to-Book ratio of 9.5x being double its peers, suggesting that investors are already paying a high price for anticipated pipeline success. Future clinical and commercial progress will need to be rapid and clear to justify the current premium valuation.
Timothy G. Youngquist 2020 Irrevocable Trust Has $10.61 Million Position in Viking Therapeutics, Inc. $VKTX
Timothy G. Youngquist 2020 Irrevocable Trust significantly increased its stake in Viking Therapeutics (VKTX) by 141.6% in the second quarter, now holding 271,849 shares valued at $10.61 million. Institutional ownership of VKTX remains high at 76.03%, with several major firms also increasing their holdings. Despite insider sales by the COO and CFO to cover tax obligations, analysts maintain a "Moderate Buy" rating with an average price target of $96.62, and the company reported a smaller-than-expected quarterly loss.
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Eli Lilly (LLY) and Novo Nordisk (NVO) dominated the GLP-1 market in May, but Truist initiated coverage on Viking Therapeutics (VKTX) with a "Buy" rating and a 162% upside target, calling it a "differentiated player." Truist highlighted Viking's VK2735 candidate and its dual oral-plus-injectable strategy as key advantages in the competitive obesity market. While LLY and NVO saw significant gains, smaller players like Viking lagged, but the new analyst coverage aims to put VKTX back on investors' radar.
Viking Therapeutics, Inc. Revenue Breakdown – NASDAQ:VKTX
The article provides a title for Viking Therapeutics, Inc. Revenue Breakdown (NASDAQ:VKTX) and indicates that it is a financial page on TradingView. However, the content primarily consists of navigation links, disclaimers, and website feature lists rather than actual revenue breakdown data. It mentions market data and reference data providers but does not display any specific financial figures.
Cornerstone Capital Inc. Takes $3.33 Million Position in Viking Therapeutics, Inc. $VKTX
Cornerstone Capital Inc. has acquired a new stake of 85,470 shares in Viking Therapeutics (NASDAQ:VKTX) worth approximately $3.33 million during the second quarter, representing 0.07% of the company. Institutional investors collectively own 76.03% of VKTX, and the stock maintains a "Moderate Buy" consensus rating from analysts with an average target price of $96.62. Despite recent price objective reductions from some firms, Viking Therapeutics reported a quarterly loss of $1.10 per share, outperforming analyst estimates.
(VKTX) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Viking Therapeutics Inc. (NASDAQ: VKTX) price dynamics, highlighting a neutral near-term sentiment that could moderate mid-term weakness. It identifies a mid-channel oscillation pattern and an exceptional short setup with a 50.5:1 risk-reward ratio. The analysis also details institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
VKTX Maintained by JP Morgan -- Price Target Lowered to $65
JP Morgan has maintained an "Overweight" rating for Viking Therapeutics (VKTX) but lowered its price target from $75 to $65, reflecting cautious optimism amid challenges in the biotechnology sector. The company has a GF Score™ of 34/100, indicating below-average performance in key financial metrics, particularly profitability, and has seen significant insider selling. Investors should consider these factors as VKTX is in a clinical stage with negative cash flow, making traditional valuation metrics difficult to apply.
